1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsFamily Caregiver Support Program (FCSP) is sponsored by Los Angeles County Department of Aging and Disabilities. The FCSP provides support to unpaid family caregivers to reduce emotional, physical, and financial strain. Services include respite care, individual counseling, support groups, and caregiver training.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Caregivers aged 18 or older providing unpaid care to an adult aged 60 or older, or providing care to someone of any age with a disability, Alzheimer's disease, or a related condition. Confirm the full requirements in the official notice before applying.
Family Caregiver Support Program (FCSP) is funded by Los Angeles County Department of Aging and Disabilities. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
FTA quietly posted a $11.96M notice for its FY2026 Innovative Coordinated Access and Mobility Pilot on July 9 with a September 9 deadline and only ~20 awards expected. Here is who is actually eligible, why the 80/20 match is easier than it looks, and the coordination-plan trap that disqualifies more applicants than any scoring criterion.
Read articleSeven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read article